Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst

Doctor holding digital tablet at meeting room

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) are trading sharply higher Tuesday morning following the release of the company’s second-quarter financial results and operational update.

What To Know: The biotechnology company posted a second-quarter net loss of $3.86 per share, which beat the analyst consensus estimate of a $10.73 loss per share. However, sales for the quarter were approximately $2.0 million, missing the estimated $2.6 million.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.